Protalix BioTherapeutics to Present at Three International Healthcare Conferences.CARMIEL, Israel -- Protalix BioTherapeutics, Inc. (Amex: PLX PLX Pharmacy, Laboratory, and Radiology (X-Ray)PLX Power Line Exchange ), today announced that Dr. David Aviezer, the Company's President and Chief Executive Officer, will be presenting at the 7th National Life Science Week, Biomed Conference and at the 2008 Bio International Convention. Additionally, the Company will be giving a presentation on its ongoing clinical development program for the treatment of Gaucher Disease Gaucher Disease Definition Gaucher disease is a rare genetic disorder that results in accumulation of fatty molecules called cerebrosides. It can have serious effects on numerous body organs including the liver, spleen, bones and central nervous system. at the 8th European Working Group on Gaucher Disease Meeting. The conference schedule is as follows: [TABLE OMITTED] About Protalix BioTherapeutics Protalix is a biopharmaceutical company. Its goal is to become a fully integrated biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins to be expressed through its proprietary plant cell based expression system. Protalix's ProCellEx(TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes is safe and scalable and will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix is enrolling and treating patients in its pivotal phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the in Israel, the United States and other locations for its lead product candidate, prGCD, for its enzyme replacement therapy Enzyme replacement therapy is a medical treatment replacing an enzyme in patients in whom that particular enzyme is deficient or absent. Usually this is done by giving the patient an intravenous (IV) infusion containing the enzyme. for Gaucher disease, a lysosomal lysosomal pertaining to or emanating from lysosomes. lysosomal enzymes enzymes located in the lysosomes. lysosomal phospholipidosis storage disorder in humans, and has reached an agreement with the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. on the final design of the pivotal phase III clinical trial through the FDA's Special Protocol Assessment (SPA) process. Protalix is also advancing additional recombinant biopharmaceutical drug development programs. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion